Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Apr;93(4):595-600.
doi: 10.1046/j.1365-2567.1998.00472.x.

Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52

S Redpath  1 , T Michaelsen, I Sandlie, M R Clark
Affiliations

Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52

S Redpath et al. Immunology. 1998 Apr.

Abstract

Activation of the complement cascade by immunoglobulin G (IgG) plays a major role in the host defense against pathogens. Using recombinant human antibodies specific for the leucocyte antigen CD52, different allotypes of human IgG1 subclass were compared for their ability to activate human complement. In addition the roles of the different length hinge regions of IgG1 and IgG3 were investigated. It was found that the naturally occurring allotypes G1m(a,z) and G1m(f), and one artificially created isoallotype, G1m(null), did not significantly differ in their overall ability to cause cell lysis. However, some differences in binding of individual components of the classical activation pathway were detected. More of the complement component C1s seemed to be associated with the allotype G1m(f), although this did not result in an overall improvement in lytic potency. In this system the wild-type IgG3 was found to be less effective in complement lysis than IgG1. By shortening the hinge region of IgG3 to resemble that of an IgG1 antibody, increased complement binding was observed compared with that of wild-type IgG3 and the IgG1 allotypes. The overall lytic potency of the antibody was also improved compared with wild type IgG3 and it was also slightly more effective than the IgG1 allotypes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nature. 1970 Feb 28;225(5235):855-7 - PubMed
    1. Biochem J. 1970 May;117(4):641-60 - PubMed
    1. J Exp Med. 1987 Nov 1;166(5):1351-61 - PubMed
    1. Nature. 1988 Mar 24;332(6162):323-7 - PubMed
    1. Nature. 1988 Apr 7;332(6164):563-4 - PubMed

Publication types

MeSH terms

LinkOut - more resources